Just in : Dexamethasone Approved by WHO For Treatment of Critically ill COVID-19 patients


On Monday, The World Health Organisation (WHO) announced that the fight against COVID-19 has received a much needed boost following “the recent finding that the steroid dexamethasone has life-saving potential for critically ill COVID-19 patients.”

During a virtual briefing from Geneva, WHP Director- General, Tedros Ghebreyesus said the next challenge is to increase production “and rapidly and equitably distribute dexamethasone worldwide, focusing on where it is needed most.”


According to Mr Ghebreyesus, "although the data on it is still preliminary,” the recent finding has given the world a much-needed reason to celebrate. He said demand has already surged, following the UK trial results showing “dexamethasone’s clear benefit”.
The Director cautioned that there is no evidence that dexamethasone works for patients who are only mildly affected, or as a preventative measure.
 
WHO said dexamethasone “should only be used for patients with severe or critical disease, under close clinical supervision.”

Read Also:COVID-19: FG Clears Air on Interstate Movement come June 21 

“There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause
harm.


“Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production,” he said.


Equally, the drug received a nod from
scientists and the international body after a UK-Government funded study showed that the low-cost steroid dexamethasone can save the life of one in eight severely ill patients on ventilators being treated for COVID-19 and of one in 25 patients who are receiving supplemental oxygen.






Premium Time#


Post a comment

0 Comments